Comparative Pharmacology
Head-to-head clinical analysis: ESTARYLLA versus LOESTRIN 21 1 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTARYLLA versus LOESTRIN 21 1 20.
ESTARYLLA vs LOESTRIN 21 1/20
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estarylla is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It suppresses gonadotropin release (FSH and LH) via estrogen and progestin, inhibiting ovulation. Additionally, it increases cervical mucus viscosity and alters endometrial receptivity, impeding sperm penetration and implantation.
Combination estrogen-progestin contraceptive; suppresses gonadotropin secretion (FSH, LH) via negative feedback, inhibiting ovulation; increases cervical mucus viscosity and alters endometrial receptivity.
One tablet (0.02 mg ethinyl estradiol and 0.15 mg desogestrel) orally once daily for 21 days, followed by 7 days of placebo. Hormone-free interval of 7 days.
One tablet orally once daily for 21 days, then 7 days off. Each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg.
None Documented
None Documented
Terminal elimination half-life of ethinyl estradiol is approximately 13-16 hours; clinical context: steady-state achieved within 5-7 days
Norethindrone: 8-11 hours (terminal half-life; steady-state achieved after 5-10 days); Ethinyl estradiol: 13-27 hours (terminal half-life; significant interindividual variability due to enterohepatic recirculation).
Renal: ~55% as metabolites, ~27% unchanged; Fecal: ~45% as metabolites
Renal: ~50% (as metabolites, primarily glucuronide conjugates of norethindrone and ethinyl estradiol); Fecal: ~35% (via bile); Urinary recovery of unchanged drug is minimal (<1%).
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive